November 04, 2025

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Conexiant

November 03, 2025

Settlement Cash: Misused or Misread?

Opioid settlement funds were used for R&B concerts promoting addiction awareness in Irvington, New Jersey, highlighting broader debates over how opioid restitution money is spent nationwide.

KFF Health News

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 28, 2025

Insurance Shake-Up: Who Loses Out?

Families nationwide face rising health insurance costs as Affordable Care Act subsidies near expiration, with premiums and deductibles projected to increase amid congressional inaction.

KFF Health News

October 27, 2025

Why Open Access May Not Boost Citations

Researchers found that companion open access journals charge high publication fees yet yield fewer citations than traditional journals.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 22, 2025

Fall Vaccines: What’s New, What’s Not

Updated CDC fall vaccine guidance simplifies covid, flu, and RSV shots with broad access and minimal changes from last year.

KFF Health News

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant